Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.
The WHO has classified aspartame which is found in diet soda as ‘possibly carcinogenic to humans,’ but experts are not ‘excessively worried’ about cancer risks.
The WHO has classified aspartame which is found in diet soda as ‘possibly carcinogenic to humans,’ but experts are not 'excessively worried' about cancer risks.
Antibody Treatment Could Fight Rare But Deadly Bile Duct Cancers djournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from djournal.com Daily Mail and Mail on Sunday newspapers.
Share:
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –
– Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval –
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ( EMA ) has validated and accepted its marketing authorization application ( MAA ) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors ( NETs ). The EMA s validation confirms that the submission is sufficiently complete and that it is ready to commence the formal review process.